MedTrace Logo

Comparison of Orcinoside With Placebo in Treatment of MDD

NCT02191384 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 186

Last updated 2021-09-23

No results posted yet for this study

Summary

The purpose of this study is to determine whether Orcinoside Capsule in different doses are effective in the treatment of Depression.

And to explore the preliminary information of safety and efficacy of Orcinoside Capsule in the Chinese Patients with Depression.

Conditions

  • Major Depressive Disorder (MDD)

Interventions

DRUG

Orcinoside

oral, twice per day

Sponsors & Collaborators

  • Kun Ming KingBio Biotechnology Co. LTD

    collaborator UNKNOWN

  • Shanghai Mental Health Center

    lead OTHER

Principal Investigators

  • Huafang LI, MD PhD · Shanghai Mental Health Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-31
Primary Completion
2016-03-09
Completion
2016-03-09

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02191384 on ClinicalTrials.gov